SAN DIEGO, Jan. 19, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of clinically
actionable liquid biopsy tests to improve the management of cancer
patients, announces that it has been awarded Australian Patent No.
2010229924 entitled, DEVICES AND METHODS OF CELL CAPTURE AND
ANALYSIS. The issued patent covers the use of antibodies in
microchannels for the capture of cancer cells or other cells that
can be used for molecular analysis in blood and other biological
fluids. Biocept has eighteen wholly-owned patents related to its
core liquid biopsy technology.
Biocept's proprietary microchannel technology enables the
capture of cells that are in low abundance, such as circulating
tumor cells (CTCs) shed into the blood by solid tumors, or fetal
cells that are present in the maternal bloodstream.
"Our liquid biopsy platform has the distinct advantage of using
both CTCs and circulating tumor DNA (ctDNA) to detect and monitor
biomarkers associated with cancer," said Lyle Arnold, Ph.D., Chief Scientific Officer at
Biocept. "Antibodies are key to our microchannel technology
that provides for the high-efficacy capture, visualization and
microscopic analysis of target cells. We have already been
granted U.S. and multiple international patents for this
technology, and we are pleased to extend this protection to
Australia."
Michael Nall, Biocept's President
and CEO, added, "The granting of patents in international markets
supports our activities to expand distribution of our liquid biopsy
platform worldwide. Our liquid biopsy tests can provide an
alternative to invasive tissue biopsies by using a simple blood
sample to obtain valuable biomarker information. This
information can be used by physicians to pursue personalized
treatments for their patients with cancer, leading to improved
outcomes."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
management, diagnosis and treatment of cancer, the ability of our
tests to provide clinically actionable information to oncologist
and their patients, and our ability to expand the distribution of
our liquid biopsy platform worldwide, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocept-awarded-patent-in-australia-for-the-use-of-antibodies-in-microchannels-to-capture-circulating-tumor-cells-and-other-rare-cells-300393179.html
SOURCE Biocept, Inc.